Discovery of [11C]MODAG-005, a novel PET tracer targeting alpha-synuclein aggregates

Ziel/Aim PET imaging of alpha-synuclein (αSYN) aggregates would be a game changer for facilitating the diagnosis of synucleinopathies and the development of novel therapies. We previously demonstrated that the structural modification of anle138b, an investigational therapeutic for synucleinopathies [1], led to radiotracer candidates with high-affinity binding to αSYN [2] [3]. Here, we report the preclinical evaluation of MODAG-005 as a promising αSYN PET tracer.